 |
 |
|
cheisi: |
The number of our direct affiliates has also grown, and we have now almost achieved complete coverage throughout the European Union. Sales of our new drugs for the treatment of asthma, the beclometasone-formoterol combination in an ecofriendly, metered-dose aerosol formulation (Foster, Innovair) have begun in several European markets, including Germany and Italy, and have been met with considerable interest among medical practitioners.
For those territories in which we are present, the products developed as a result of our internal R&D activities are becoming increasingly prominent in our affiliates’ portfolios, and this has further established respect for the image and reputation of our Group.
Modulite technology, which is the basis of all our product formulations in metered-dose aerosols, is also proving to be a key device for innovation, and has recently received significant recognition for its originality in Europe.
Our Research and Development activities have also continued to evolve, in the quest for consistently better organisational efficiency and technological efficacy: a radical, broad-scale project has been undertaken to change the development processes in various research projects, in order to ensure their completion by pre-set deadlines.
►Mission & Vision Darmanyab Darou's first objective is making health accessible to ...
►Business Development Darmanyab Darou is a fast growing company with an active ...
the best resolution for view: 1280 x 1024